Aradhana Kasimsetty, Doctoral Candidate at the Perelman School of Medicine, shared on LinkedIn:

“With the recent FDA guidances on gene therapy products, risk management and concerns of vector-derived malignancies are at the forefront of clinical development.

As part of the special issue “Liver Directed Adeno‐Associated Virus Gene Therapy”, Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer and how integration site monitoring synergizes with routine patient care after liver-directed gene therapy.

Integration and the risk of liver cancer—Is there a real risk?”

Additional information.
Source: Aradhana Kasimsetty/LinkedIn